Sugi Predict

Sugi Predict / Targets / AURKB

AURKB

Aurora kinase B · Q96GD4 · AURKB on Sugi Atlas →

279,766 patent compounds predicted against AURKB, 179,282 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL75540 SCHEMBL75540 0.61 17/20
SCHEMBL75557 SCHEMBL75557 0.60 17/20
SCHEMBL75538 SCHEMBL75538 0.58 17/20
SCHEMBL75731 SCHEMBL75731 0.58 17/20
SCHEMBL91082 SCHEMBL91082 0.74 16/20
SCHEMBL75628 SCHEMBL75628 0.59 16/20
SCHEMBL75558 SCHEMBL75558 0.62 15/20
SCHEMBL75629 SCHEMBL75629 0.59 15/20
SCHEMBL91083 SCHEMBL91083 0.50 15/20
SCHEMBL75631 SCHEMBL75631 0.76 13/20
SCHEMBL75584 SCHEMBL75584 0.75 13/20
SCHEMBL91085 SCHEMBL91085 0.49 13/20
Inamrinone Inamrinone (SCHEMBL44012) 1.00 12/20
SCHEMBL75646 SCHEMBL75646 0.61 12/20
SCHEMBL91081 SCHEMBL91081 0.61 12/20
SCHEMBL61900 SCHEMBL61900 0.56 10/20
SCHEMBL62264 SCHEMBL62264 0.51 10/20
SCHEMBL100362 SCHEMBL100362 0.54 9/20
SCHEMBL82562 SCHEMBL82562 0.39 8/20
SCHEMBL84573 SCHEMBL84573 0.52 7/20

Clinical trials — most relevant to AURKB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression PHASE3RECRUITING
Study of MLN8237 in Combination With Irinotecan and Temozolomide PHASE1/PHASE2COMPLETED
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma PHASE2COMPLETED
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL PHASE2RECRUITING
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma PHASE1/PHASE2COMPLETED
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer PHASE1RECRUITING
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors PHASE1COMPLETED
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies PHASE1COMPLETED
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors PHASE1COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. nanRECRUITING
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AURKB binder may also engage these)

ProteinNameSimilarity
Q7YRC6 — 0.999 Q7YRC6 →
Q6NW76 — 0.999 Q6NW76 →
A4IGM9 — 0.998 A4IGM9 →
O70126 — 0.998 O70126 →
AURKC Aurora kinase C 0.997 landscape →
Q9N0X0 — 0.996 Q9N0X0 →
Q755C4 — 0.994 Q755C4 →
O55099 — 0.994 O55099 →
Q6GPL3 — 0.993 Q6GPL3 →
O59790 — 0.993 O59790 →
Q9VKN7 — 0.992 Q9VKN7 →
Q384J7 — 0.992 Q384J7 →
P10665 — 0.992 P10665 →
Q6PFQ0 — 0.991 Q6PFQ0 →
Q63531 — 0.990 Q63531 →
Q91820 — 0.990 Q91820 →
RPS6KA1 Ribosomal protein S6 kinase alpha-1 0.990 landscape →
P97477 — 0.990 P97477 →
Q6DE08 — 0.989 Q6DE08 →
D7UQM5 — 0.989 D7UQM5 →
P51138 — 0.988 P51138 →
Q6C3J2 — 0.988 Q6C3J2 →
Q8BRK8 — 0.988 Q8BRK8 →
Q66JF3 — 0.988 Q66JF3 →
Q21734 — 0.988 Q21734 →
PHKG2 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform 0.988 landscape →
P18654 — 0.988 P18654 →
A5GFW1 — 0.988 A5GFW1 →
Q96QS6 — 0.988 Q96QS6 →
RPS6KA3 Ribosomal protein S6 kinase alpha-3 0.988 landscape →